复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

交易中 06-09 10:51:31

15.830

-0.060

-0.38%

最高16.050	最低15.560	成交量146.25万
今开15.890	昨收15.890	日振幅3.08%
总市值420.92亿	流通市值85.64亿	总股本26.59亿
成交额2,302万	换手率0.27%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":15.83,"timestamp":1780973485008,"preClose":15.89,"halted":0,"volume":1462500,"delay":0,"changeRate":-0.0037759597230963182,"floatShares":540971500,"shares":2659000000,"eps":1.27,"marketStatus":"交易中","change":-0.06,"latestTime":"06-09 10:51:31","open":15.89,"high":16.05,"low":15.56,"amount":23023835,"amplitude":0.030837,"askPrice":15.84,"askSize":7000,"bidPrice":15.83,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.488877,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1780977600000},"marketStatusCode":2,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":15.89,"dividendRate":0.02211,"openAndCloseTimeList":[[1780968600000,1780977600000],[1780981200000,1780992000000]],"volumeRatio":1.653251,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":21.74,"timestamp":1780973489000,"preClose":21.65,"halted":0,"volume":6552700,"delay":0,"premium":"-36.99"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2641611953","title":"复星医药：向权益分派实施公告指定的股权登记日可参与分配的股东每10股派发现金红利人民币3.90元（税前）","url":"https://stock-news.laohu8.com/highlight/detail?id=2641611953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641611953?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:18","pubTimestamp":1780651117,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药(600196)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：啥时分红，亏大发了，尽快分红复星医药回复：投资者您好！公司2025年度利润分配预案尚待2025年度股东会（将于2026年6月16日召开）批准，本次利润分配预案为向权益分派实施公告指定的股权登记日可参与分配的股东每10股派发现金红利人民币3.90元（税前）。有关本次分红的具体安排，请留意公司后续发布的临时公告。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500029774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","02196","BK0060","MUCmain","BK0239","UCmain","BK0028","MCNHmain","BK1191","BK0188","CYB","BK0012","BK1515","BK1593","BK0196","BK0096","CNHmain","BK0187","600196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128122169","title":"复星医药更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1128122169","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128122169?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:32","pubTimestamp":1780561924,"startTime":"0","endTime":"0","summary":"上海复星医药(集团)股份有限公司于2026年6月4日发布2026年5月股份变动月报表，披露了截至2026年5月31日的股本情况。本报告期内，公司法定注册股本维持在人民币2,670,429,325元，其中H股为551,940,500股，A股为2,118,488,825股，面值均为人民币1元。同时，公司2025年H股受限制股份单位计划已授出但尚未归属的受限制股份单位为10,382,200份，与上期一致。公司表示，已遵守香港联合交易所有限公司上市规则及相关法律法规的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640970576","title":"复星医药：2025年及2026年第一季度业绩稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2640970576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640970576?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:12","pubTimestamp":1780477944,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药06月03日在投资者关系平台上答复投资者关心的问题。得益于创新研发与国际化运营的深度耦合，公司2025年及2026年第一季度业绩稳健增长。2025年8月公告的新一期股权激励方案中也明确2025年至2027年归母净利润及创新药品收入每年增长近20%的业绩考核目标，确定了公司聚焦创新资产，坚持高质量发展的行动方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","02196","BK0175","BK0188","BK0060","BK0028","BK0183","BK0187","BK1515","BK1593","600196","BK0239","BK0096","BK0012","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640597503","title":"医美概念承压 巨子生物(02367)领跌4.08% 机构指敷料药店渠道红利消退、行业进入存量竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2640597503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640597503?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:39","pubTimestamp":1780465177,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念普跌，截至发稿，巨子生物(02367)跌4.08%，医思健康(02138)跌3.66%，复星医药(02196)跌3.16%，康哲药业(00867)跌2.53%，四环医药(00460)跌2.08%，三生制药(01530)跌2.07%。消息面上，华龙证券新近研究指，当前医美行业政策端医保支付监管收紧，医美敷料药店渠道红利消退，行业合规化监管持续深化；医美行业进入存量竞争，循证诊疗、合规经营、精细化运营成为机构发展核心方向。产业端AI智能设备、数字化服务加速在美业线下场景渗透，数智化转型成为行业新趋势，区域美业展会加速全产业链资源整合与模式创新。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982967","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNP33.GBP","SG9999004220.SGD","BK1593","BK1583","SG9999015986.USD","SG9999015952.SGD","SG9999015978.USD","BK1511","02196","00460","IE00BMCWC346.EUR","SG9999015945.SGD","BK1515","BK1161","BK1600","BK1207","02367","00867","IE00BYV24P56.USD","IE00BVYPNQ40.USD","01530","02138","BK1215","BK1191","HK0000165453.HKD","IE00BGHQDM52.EUR","SG9999004311.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640673927","title":"创新药研发及商业化加速 复星国际(00656)“最强估值锚点”夯实确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2640673927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640673927?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:30","pubTimestamp":1780450200,"startTime":"0","endTime":"0","summary":"创新药步入收获期，全球市场商业潜力加速兑现近年来，在创新及全球化两大引擎的推动下，复星的创新药持续在全球市场商业放量，成为其重要的增长极。随着复星创新药进入商业化放量周期，其利润贡献和估值支撑能力都在明显增强。其中，花旗着重指出，基于向好的基本面情况，预计复星国际2026年业绩表现强劲。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK1515","BK1593","BK1574","BK1230","00656","06978","159992","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640983626","title":"股市必读：复星医药（600196）5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640983626","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640983626?lang=zh_cn&edition=full","pubTime":"2026-06-01 01:28","pubTimestamp":1780248491,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，复星医药报收于23.25元，上涨2.2%，换手率1.24%，成交量26.17万手，成交额6.07亿元。复星医药关于参与设立私募股权投资基金进展的公告2026年5月28日，复星医药控股企业苏州君明与其他7方投资人签订《杭州基金合伙合同》，共同设立杭州基金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100000614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0175","BK0012","BK0183","BK0028","BK0239","BK0196","BK0096","BK0188","BK1593","BK1515","02196","600196","BK1191","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601490","title":"每周股票复盘：复星医药（600196）复宏汉霖帕妥珠单抗获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639601490?lang=zh_cn&edition=full","pubTime":"2026-05-31 01:57","pubTimestamp":1780163829,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，复星医药报收于23.25元，较上周的23.4元下跌0.64%。本周关注点公司公告汇总：复宏汉霖帕妥珠单抗注射液获国家药监局批准上市。复星医药控股子公司复宏汉霖自主研发的帕妥珠单抗注射液获国家药品监督管理局批准上市，适应症覆盖早期乳腺癌和转移性乳腺癌。该药品为帕妥珠单抗生物类似药，已获美国FDA、欧盟委员会批准，并获加拿大卫生部受理。2025年中国境内帕妥珠单抗产品销售额约为27.28亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","02196","600196","HK0000306685.HKD","BK0028","BK0175","BK1593","BK1515","BK0187","BK0183","02696","BK0188","HK0000320264.USD","BK0196","BK0060","HK0000165453.HKD","BK0096","BK0012","BK1161","BK1191","HK0000320223.HKD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639622925","title":"智翔金泰GR1803授权复星医药：18.2亿元交易落地，股价为何大跌逾9%？","url":"https://stock-news.laohu8.com/highlight/detail?id=2639622925","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639622925?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:56","pubTimestamp":1780055789,"startTime":"0","endTime":"0","summary":"一则涉及高达18.2亿元的重磅授权公告，并未给智翔金泰（SH688443）的股价带来提振。5月29日，公司股价开盘即震荡走低，盘中最大跌幅超过9%，截至收盘报26.80元，单日下跌9.18%，总市值回落至约98.27亿元。而在前一日晚间，公司刚刚宣布与复星医药控股子公司药友制药就核心管线GR1803达成大中华区独家授权合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605293754629730.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754629730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0187","BK0183","BK0196","BK1515","BK1593","BK1191","BK0239","BK0012","600196","BK0096","BK0175","02196","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639962860","title":"复星医药(600196.SH)控股子公司帕妥珠单抗注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2639962860","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639962860?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:41","pubTimestamp":1780044063,"startTime":"0","endTime":"0","summary":"2、转移性乳腺癌：与曲妥珠单抗和多西他赛联合，适用于既往未接受过针对转移性乳腺癌的抗HER2治疗或者化疗的HER2阳性、转移性或不可切除的局部复发性乳腺癌患者治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0188","BK0196","600196","BK0239","BK1191","BK0028","02196","BK0060","BK0175","BK1593","BK1515","BK0187","BK0096","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638691435","title":"复星医药（600196）披露控股子公司签订许可协议的公告，5月28日股价下跌2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638691435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638691435?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:14","pubTimestamp":1779977657,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，复星医药报收于22.75元，较前一交易日下跌2.44%，最新总市值为607.52亿元。该股当日开盘23.21元，最高23.35元，最低22.64元，成交额达3.75亿元，换手率为0.77%。近日，复星医药披露《关于控股子公司签订许可协议的公告》。该事项已经公司第十届董事会第三十一次会议审议通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0187","BK1191","BK0175","BK1515","BK0239","BK0096","600196","BK0188","BK0028","BK0196","BK0012","02196","BK0060","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638102669","title":"复星医药最新公告：控股子公司获智翔金泰GR1803双抗许可总付款上限6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638102669","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638102669?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:26","pubTimestamp":1779960418,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司药友制药与智翔金泰签订许可协议，获授予GR1803双特异性抗体在中国境内及港澳台地区的临床开发、商业化独占权利及生产排他权利，并将作为该产品的上市许可持有人。药友制药将向智翔金泰支付至多6亿元，包括首付款3亿元、上市里程碑2.5亿元及技转里程碑0.5亿元，并基于年度净销售额支付销售里程碑及销售提成。GR1803拟用于治疗多发性骨髓瘤、系统性红斑狼疮等，其附条件上市申请已获国家药监局受理并纳入优先审评。本次许可旨在丰富公司在血液瘤领域的产品管线。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800030921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0175","BK0239","BK1593","BK0188","BK1191","BK0187","BK0060","BK0196","BK1515","BK0096","02196","BK0183","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638245485","title":"复星医药子公司拟参投星曜坤泽，后者尚无产品上市，去年1至10月亏损1808万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638245485","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638245485?lang=zh_cn&edition=full","pubTime":"2026-05-27 08:52","pubTimestamp":1779843140,"startTime":"0","endTime":"0","summary":"5月26日晚间，复星医药（600196）发布公告称，公司控股子公司复星医药产业拟出资共计4.14亿元与其他新投资方共同参与星曜坤泽B轮融资并受让本公司联营公司苏州基金、天津基金所持有的星曜坤泽（下称“标的公司”）部分股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605273750375029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK1593","IPOS","BK1191","600196","BK0060","BK0096","02196","BK0028","BK0175","BK0187","BK0183","BK1515","BK0239","BK0196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638438235","title":"复星医药（600196）披露对外投资暨关联交易公告，5月26日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638438235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638438235?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:24","pubTimestamp":1779805464,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，复星医药报收于23.17元，较前一交易日下跌0.56%，最新总市值为618.74亿元。近日，复星医药发布《关于对外投资暨关联交易的公告》。公告显示，公司控股子公司复星医药产业拟出资41,437.50万元参与星曜坤泽B轮融资并受让苏州基金、天津基金所持股权，其中21,781.3912万元用于认缴新增注册资本，19,656.1088万元用于受让股权。交易完成后，预计持有星曜坤泽20.8709%股权。本次投资已获董事会审议通过，无需提交股东大会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0028","BK0175","BK0188","600196","BK0196","BK0060","BK0096","BK1593","BK1191","BK0239","BK1515","02196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638597731","title":"复星医药：控股子公司出资4.14亿元参与星曜坤泽B轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2638597731","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638597731?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:04","pubTimestamp":1779786240,"startTime":"0","endTime":"0","summary":"南财智讯5月26日电，复星医药公告，控股子公司上海复星医药产业发展有限公司拟出资共计人民币41437.50万元，其中21781.39万元用于认缴苏州星曜坤泽生物医药股份有限公司新增注册资本293.68万元，19656.11万元用于受让苏州基金及天津基金合计持有的星曜坤泽存续注册资本308.65万元；交易完成后，复星医药产业预计将持有星曜坤泽20.87%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605263749758734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK0012","BK0188","BK0187","BK0183","BK0060","BK1593","BK0096","BK0028","BK0175","600196","BK0239","02196","BK0196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637733973","title":"每周股票复盘：复星医药（600196）多款新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637733973","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637733973?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:09","pubTimestamp":1779559752,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，复星医药报收于23.4元，较上周的24.13元下跌3.03%。复星医药控股子公司复宏汉霖自主研发的HLX3902注射液获澳大利亚人类研究伦理委员会批准，并完成澳大利亚药品管理局备案，允许在澳开展Ⅰ期临床试验，系该药品全球首次获得临床试验许可。复星医药控股子公司重庆药友制药有限责任公司获得国家药品监督管理局批准，其左氧氟沙星注射液正式获准上市。该药品已获中国临床试验批准及澳大利亚药品管理局备案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","BK1191","BK1593","600196","BK0012","02196","BK0060","BK0196","BK1515","BK0188","BK0187","BK0028","BK0175","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637381906","title":"复星医药(02196)控股子公司就左氧氟沙星注射液的药品注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637381906","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637381906?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:50","pubTimestamp":1779357023,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，上海复星医药(集团)股份有限公司控股子公司重庆药友制药有限责任公司就左氧氟沙星注射液的药品注册申请获国家药品监督管理局批准。截至2026年4月，本集团现阶段针对该药品的累计研发投入约为人民币194万元。根据IQVIACHPA最新数据，2025年，左氧氟沙星注射剂于中国境内的销售额约为人民币10.57亿元。该药品本次获批上市，将进一步丰富本集团产品线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0028","BK0175","BK0239","BK1593","BK0188","BK1191","BK0187","BK0060","BK0196","BK1515","BK0096","02196","BK0183","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109022016","title":"复星医药左氧氟沙星注射剂新药注册申请获中国药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1109022016","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109022016?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:46","pubTimestamp":1779356798,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司宣布，其提交的左氧氟沙星注射剂新药注册申请，已获得中国国家药品监督管理局的正式批准。这一进展标志着该产品在中国市场上市销售的关键监管障碍已被清除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0028","BK0183","BK0060","BK1515","BK0196","BK1191","BK0239","BK0187","600196","02196","BK1593","BK0012","BK0175","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637386195","title":"复星医药(600196.SH)子公司HLX3902注射液获准于澳大利亚开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2637386195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637386195?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:47","pubTimestamp":1779353268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)自主研发的HLX3902注射液(即STEAP1xCD3xCD28三特异性抗体)用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗的Ⅰ期临床试验方案获得相关人类研究伦理委员会的批准、并通过澳大利亚药品管理局(Therapeutic Goods Administration)备案，系该药品于全球范围内取得的首个临床试验许可。复宏汉霖拟于条件具备后于澳大利亚开展该药品的相关临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","02196","BK1191","BK0188","BK0012","BK1593","BK0060","BK1515","BK0096","BK0239","BK0187","600196","BK0196","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636849445","title":"复星医药：截至2026年5月20日本集团无逾期担保事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2636849445","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636849445?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:54","pubTimestamp":1779274440,"startTime":"0","endTime":"0","summary":"5月20日，复星医药发布公告称，截至2026年5月20日，包括本次担保在内，本集团实际对外担保金额折合人民币约2，121，217万元，约占2025年12月31日本集团经审计的归属于上市公司股东净资产的43.52%；均为本公司与控股子公司/单位之间、控股子公司/单位之间发生的担保。截至2026年5月20日，本集团无逾期担保事项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743672945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0012","BK0188","02196","BK1515","BK1593","BK0028","BK0183","600196","BK0060","BK0196","BK0187","BK0239","BK1191","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636061617","title":"每周股票复盘：复星医药（600196）获阿尔茨海默病新药全球开发选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2636061617","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636061617?lang=zh_cn&edition=full","pubTime":"2026-05-17 01:56","pubTimestamp":1778954171,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，复星医药报收于24.13元，较上周的24.82元下跌2.78%。本周，复星医药5月12日盘中最高价报25.62元。本周关注点来自公司公告汇总：复星医药产业获授AR1001分子用于治疗阿尔茨海默病的全球多中心III期临床试验后90天内独家选择权。来自公司公告汇总：复星医药控股子公司桃红四物汤颗粒注册申请获国家药监局受理。协议涉及选择权费6000万美元，后续首付款及里程碑付款最高达1.8亿美元，另按销售分成支付。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0188","BK0060","BK0096","BK1515","600196","BK0028","BK0187","BK0012","BK1191","BK0183","BK0196","02196","BK0175","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0735},{"period":"1month","weight":-0.1668},{"period":"3month","weight":-0.1999},{"period":"6month","weight":-0.2874},{"period":"1year","weight":-0.0205},{"period":"ytd","weight":-0.1872}],"compareEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0502},{"period":"6month","weight":-0.0346},{"period":"1year","weight":0.0363},{"period":"ytd","weight":-0.038}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036178},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044258},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026005},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024934},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.029391},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}